Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SXPT news not even showing..
on Etrade yet. WTF? It does show on yahoo though.
SXPT -> Ain't filling... :(
SXPT rumor..
SXPT may become added as a sponsored link at Yahoo travel which will include travel packages for the 2008 Olympics. If this happens, holy crap...
I will try and work on more concrete info but someone stated SXPT was to release news this week? Anyone confirm?
SXPT --> float = 1.3 million..eom
SXPT had my order in...
at 930am did not fill until 942am and they did not even show the buy..
SXPT - holy buy..eom
Email from company:
Dear xxxxx,
Thank you for your encouragement and questions
regarding Sino Express Travel. PKF International
was appointed as our external auditor in November 2005.
They are responsible for Sino's US GAAP audit work and
financial governance.
Sino Express has aggressive growth plans for 2006 which
we believe will be in the interests of our shareholders.
Moving to a higher trading market is also part of
the plan.
Cheers
Xia Chen
Sino Express Travel Limited
www.sinoexpresstravel.com
"Greater China's Premier Travel Services"
Sino listed here:
http://www.itravelsys.com/business.htm
This is huge news..
for Sino:
Sino Express ties up with Wing On
Tuesday, December 06 2005 @ 03:54 PM GMT
Sino Express Travel is entering into a strategic alliance with International Travel Systems Inc. (ITS), a wholly owned division of Wing On Travel (Holdings) Limited.
Wing On is one of the largest Asian travel companies listed on the Hong Kong stock exchange.
ITS will offer its B2B trading systems to Sino's hotel rooms resellers and to enhance Sino's online travel booking system www.v222.com.
Xia Chen, CEO of Sino Express Travel commented, "The ITS trading platform will provide our resellers with real time pricing, availability and analytic information on our hotel rooms inventory. The revamp of our online hotel and flight booking site will significantly enhance our service offering for our clients."
This partnership makes Sino Express Travel Ltd the third travel operator in Asia to adopt the ITS system following Wing On Travel and China Hotel Net (CHN), two other major travel and hotel booking service providers in the Greater China region. Xia Chen further commented, "Sino Express will stay committed to its technology adaptation in order to provide more competitive services.
The technology upgrade will also provide Sino with future business opportunities with other users of the ITS system."
Sino Express Travel Limited -- www.sinoexpresstravel.com -- together with its 100 percent owned subsidiaries, GS Travel (Hong Kong) Ltd and www.v222.com , is an international travel company with operating offices in Hong Kong, Beijing, Guangzhou, Vancouver, Toronto and Seattle. Sino intends to grow its business by acquiring and operating a diversified travel business portfolio, seeking to invest in profitable travel related companies with reputable management and high growth potential. Wing On Travel is a major shareholder of Sino Express.
--------------------------------------------------------------------------------
I posted your message..
at CTRP & LONG as well. Look how small their revenues are compared to their market cap. Same field. This thing can turn into a monster. Small float to boot!
Chinese Travel plays..
Is this a hot market about to develop? I think SXPT is going to benefit from this. Look at this article from yesterday:
Friday January 27, 11:58 AM
Chinese Online Travel Service to List on Nasdaq
BEIJING, Jan 27 Asia Pulse - Anticipating more travellers will use the Internet to book tickets and hotels, Guangdong China Travel Service (Holdings) Ltd (GDCTS) said yesterday it will list its joint venture online travel service on the NASDAQ next year.
GDCTS, the province's leading tour agency, teamed up with Hong Kong-listed Wing On Travel Holding Ltd (SEHK:1189) in a 50-50 joint venture to launch online travel service Travoo China Limited on Wednesday.
Travoo received 50 million yuan (US$6.2 million) investment from both parent companies. Travoo China is expected to be listed on the NASDAQ within 18 months.
Many mainland and Hong Kong travel agencies are trying to grab a slice of the mainland's rising online travel market, GDCTS said.
Inspired by last year's strong performances of Ctrip and eLong, two NASDAQ-listed Chinese online travel service providers, GDCTS and Wing On decided to follow suit.
Xu Yongsheng, director of GDCTS and chairman of Travoo China, said the new website should help customers benefit from access to hotels, car rentals and vacation packages.
TZOO..
I posted your message about SXPT over on the yahoo TZOO board. TZOO has a 350 million market cap on 47 million in ttm sales. Getting SXPT to say a 100 million cap would put the share price around $2. Not far fetched being China stocks are hot and this should grow earnings well. Thoughts?
Great charts...
Thanks for updating. This reminds me of the trading on NNVC. I watched it in this area with this kind of volume then bam, it busted to $1 in no time. Plus the float here is only 1.3 million and the olympics are coming? Incredible.
Good luck all.
Short interest released..
Friday , January 20, 2006 16:17 ET
According to new short interest data from AMEX, short interest for Sulphco Inc (AMEX: SUF) DECREASED 13.9% to 2,326,539 shares for the month ended mid-January, 2006.
SYMBOL = SUF
DECEMBER = 2,701,284
JANUARY = 2,326,539
CHANGE = -374,745
%CHANGE = -13.87%
DAYS/COVER = 2
Still a large amount of shares short even after this run! Can you say KABOOM!
Gave you NNLX at .11 - going to $1+?
Who's buying my NNLX...
Impossible to fill, and now up to .13.
NNLX - last 4 headlines...
12/19 - NanoLogix Management Opposing Hostile Takeover Bid of Company Patents
1/4 - NanoLogix Expands Board
1/12 - NanoLogix Receives Financing Commitment and Strategic Assistance From U.S. Investment Fund
1/18 - NanoLogix Initiates Activities To Attain Fully Reporting Status
Diamond in the rough here for .11? We shall see...
Hydrogen Bioreactor information:
NanoLogix Study Confirms Early Success Of Hydrogen Bioreactor
NanoLogix, Inc., a Nanobiotechnology company engaged in the research, development and commercialization of technologies for the production of bacteria and disease testing kits, alternative sources of fuel, cancer therapy and remediation of toxic materials, announces that preliminary data and results of a study which confirms laboratory proof-of-concept measurements have shown it possible to generate hydrogen in high yields via the use and adaptation of its intellectual property. In this study, the bioreactor produced biogas consisting of 50% hydrogen by volume, without any trace of methane.
Recently, NanoLogix, Inc. (formerly Infectech, Inc.) signed a feasibility study with the Department of Environmental Science and Engineering of Gannon University in Erie, PA to develop a bioreactor which utilizes NanoLogix's patented bacterial culturing methods in order to produce hydrogen inexpensively. Hydrogen reacts with oxygen to yield significant amounts of energy, and has the added benefit of not producing carbon dioxide as a by-product (the reaction between hydrogen and oxygen simply generates water vapor). NanoLogix believes they have discovered the most likely method for low cost production of massive quantities of hydrogen as an alternate energy source. NanoLogix has ascertained through its patent counsel that additional patents will be pending beyond those already filed.
NanoLogix, Inc., formerly known as Infectech, Inc. (http://www.infectech.com), is a technology application innovator of biogas products and services designed to assist in worldwide energy independence and reduce pollution from renewable, environmentally-friendly energy sources. NanoLogix is also engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious human diseases. The Company's patents span the identification and antibiotic sensitivity testing of 34 disease-producing bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS. Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a genetically based induction of "cell suicide" in cells. The Company's 31 patents can be viewed by visiting http://www.infectech.com/intellectual_property.php .
The convergence of science, medicine and technology is on the cusp of yielding extraordinary breakthroughs. Today, patents that were once designed to identify bacteria have widespread applications across multiple markets. At the heart of this convergence is nature. All things begin and end with the building blocks of life. NanoLogix's portfolio of 31 patents have yielded a method vital to the development of biophasic system devices intended for medical purposes to cultivate and identify certain pathogenic microorganisms. The devices contain one or more components that suppress the growth of certain microorganisms while either promoting or not affecting the growth of other microorganisms. The FDA registered devices aid in the diagnosis of disease caused by the pathogenic microorganisms. products, a method for low cost hydrogen production, a genomic cancer therapy and methods for cleaning up toxic environments using bioremediation.
NanoLogix's patents have nanotechnology applications in medical drugs/devices, bio-defense sensors, hydrogen production, cancer treatment and bioremediation. Nanotechnology applications include Biochips embedded in small transportable devices for rapid bacteria identification of disease causing pathogens, and Bio Micro Electro Mechanical Systems ("BioMEMS") for rapid environmental microbial monitoring with bio-defense implications. Its hydrogen bioreactor research is designed to assist in worldwide energy independence and reduce pollution using renewable, environmentally-friendly energy sources. NanoLogix's FDA registered diagnostic test kits are designed to be used for the rapid identification of infectious human diseases and identify 34 disease-producing bacteria, including Tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), Pseudomonas, and Nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS, as well as in patients undergoing surgery. Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a genetically based induction of "cell suicide" in cells. It therefore serves as the foundation for cancer therapy. NanoLogix's other patents include technology designed for use in the bioremediation of contaminated soil and water.
Grape Jelly Waste For Hydrogen Production: Nanologix & Welch Foods Inc
October 28, 2005 07:30 AM - John Laumer, Philadelphia
http://www.treehugger.com/files/2005/10/grape_jelly_was.php
Anyone else get in?
Found today's news quite interesting. Will add links as time allows.
NNLX +100%, in a hostile takeover battle...
with Nutra Pharma (+53% today). NanoLogix says:
-NanoLogix management secured a fairness opinion and analysis from an independent CPA firm and the Company's general counsel. The conclusion reached by both parties suggests that Nutra Pharma's demands would be grossly unfair to the Company and to its shareholders. In particular, noted the analysis, "the consideration offered by Nutra Pharma is not commensurate with what we believe the current fair market value of the intellectual property to be with respect to perceived and potential future value."
-CEO of NanoLogix, Dr. Mitch Felder, commented, "Nutra Pharma is all too aware of the real potential economic value of NanoLogix's patent portfolio. While we want to continue our relationship with Nutra Pharma, we are not willing to release the principal assets of NanoLogix for anything less than fair value. Nutra Pharma's demands are clearly not in the best interest of the company and its shareholders. If Nutra Pharma were to agree to reasonable terms, we would consider a transfer of our intellectual property."
-Randall S. Goulding, NanoLogix's General Counsel stated, "Effectively, what Nutra Pharma was trying to do is to acquire all of the assets of NanoLogix at a fraction of their intrinsic value. Their 'offer,' if that is what you want to call it, is grossly unfair, egregious and is overreaching." He continued, "Recognizing the inherent value of the patent portfolio, we have introduced the Company to various strategic investors to assure that the Bioreactor Facility will be constructed pursuant to the agreement with Welch's as well as to provide funding to bring to market and monetize the remainder of the Company's patent portfolio."
NNLX gonna fly north of $1 imo.
NanoLogix, Inc. (IFEC) NanoLogix, Inc., formerly known as InfectTech, Inc., is a technology application innovator of biogas products and services designed to assist in worldwide energy independence and reduce pollution from renewable, environmentally-friendly energy sources. NanoLogix is also engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious human diseases. The Company's patents span the identification and antibiotic sensitivity testing of 34 disease-producing bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS. Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a genetically based induction of "cell suicide" in cells.
EESV - nice natural gas news...HOD..eom
EESV - stock up..
-22 of 23 days
-share buyback began today
-recent gas just discovered
-news this week of second (larger) well findings
-natual gas going to $20
Thoughts on how high this can go?
EESV - buyback
only started today. wow :)
MBTT - 43 O/S & only a 3 million market cap? WOW!
Doubloon..
We cross paths again. Haven't talked to you since the GMED days over at RB. Was looking for an oil/gas play and stumbled across this board.
What are your thoughts on the following link announced yesterday. I got in average .201. Market cap only $25 million and this news looks huge. What is your take on the reserves/income numbers? What I also like is there is no debt financing here. Thanks!
http://www.knobias.com/individual/public/news.htm?eid=3.1.3cdc95b6750aeaa147ecd014b669b45a8cc3a69a12...
PRVB - broke 200 day. Huge news yesterday pm.
PRVB - Check the Reserve/Income numbers:
http://www.knobias.com/individual/public/news.htm?eid=3.1.3cdc95b6750aeaa147ecd014b669b45a8cc3a69a12...
Can you say Ca'Ching!
PRVB - bell buy with that news..eom
PRVB - market cap only $26 million..eom
Best part of PRVB news...
read the last sentence.
Powder River Basin Gas Corp. (PRVB) announced it has completed the purchase of an Oil and Gas project in Goliad County, Texas, containing approximately 2500 acres of proven reserves. An independent engineering report completed on November 21, 2005 shows proven reserves of 776,000 barrels of oil and 17.4 BCF of gas. This property immediately adds proven reserves Discounted at P.V. 10% of $77,389,500 to Powder River Basin Gas Corp.'s holdings. The Company plans to drill 14 wells in the Gulf Coast Frio sand, which is under 4000 feet.
Drilling on the project will commence immediately following the holiday season, with the first wells expected to be in production by the end of January, 2006. Gas infrastructure is in place. Due to confidentiality agreements between all parties the price and terms of the purchase will not be disclosed at this time, however it is a cash purchase with no stock in PRVB involved.
Where do you see it opening?
3dcg..
Keep the updates coming. Thanks!
GSHF - .20 by lunch? eom
GSHF - rolling. Net asset value .28/share.
GSHF - Net asset value per share = .28
can you say easy double from here?
Anyone know the float there?
TIA
INSQ - moving :)
Where's 50mil?
INSQ - green...eom